- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Innate Pharma (IPH)
Innate Pharma stock price live, this page displays EPA IPH stock exchange data. View the IPH premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Innate Pharma real time stock price chart below.
What Is the Innate Pharma Stock Price Today?
The Innate Pharma stock price today is 1.8380.
What Is the Stock Symbol for Innate Pharma?
The stock symbol for Innate Pharma is ""IPH.""
What Stock Exchange Does Innate Pharma Trade On?
Innate Pharma is listed and trades on the Paris stock exchange.
Is Innate Pharma a Good Stock to Buy?
Determining whether Innate Pharma—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the IPH quote. (ISIN: FR0010331421)
What Is the Innate Pharma Stock Price Today?
The Innate Pharma stock price today is 1.8380.
What Is the Stock Symbol for Innate Pharma?
The stock symbol for Innate Pharma is ""IPH.""
What Stock Exchange Does Innate Pharma Trade On?
Innate Pharma is listed and trades on the Paris stock exchange.
Is Innate Pharma a Good Stock to Buy?
Determining whether Innate Pharma—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the IPH quote. (ISIN: FR0010331421)
1.8380
-0.1100(-5.65%)
Closed·
Fair Value
An estimate of a Innate Pharma's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
1.8280
1.9420
52 wk Range
1.3300
2.5000
IPH Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
IPH is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a Innate Pharma's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
1.82801.9420
52 wk Range
1.33002.5000
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
IPH Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a Innate Pharma's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PricePrice Target
4.8433
Upside
+163.51%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Quickly burning through cash
- Form 6K Innate Pharma SA For: 29 July
- Investing.com
- Form 6K Innate Pharma SA For: 4 August
- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Sell
Innate Pharma Company Profile
Innate Pharma S.A. operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally. The company’s products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. Its products in preclinical trials are IPH43, an anti-MICA/B ADC and IPH45, an antibody drug conjugates (ADC); and IPH67, an undisclosed, multi-specific ANKET. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. Innate Pharma S.A. was incorporated in 1999 and is based in Marseille, France.
Innate Pharma Earnings Call Summary for Q2/2025
- Revenue of $4.9M in H1 2025; cash position of $70.4M expected to support operations until Q3 2026
- Strategic refocus on key assets: IPH4502, Lacutamab, and Monalizumab; streamlining operations to reduce costs
- Lacutamab received FDA breakthrough therapy designation; Phase 3 trial start expected in 2026
- Operating expenses of $30.3M, with $20.5M allocated to R&D (29% YoY decrease)
- Preliminary data for IPH4502 expected in H1 2026; Monalizumab Phase 3 data anticipated in H2 2026
Last Updated: 17/09/2025, 14:28
Read Full TranscriptCompare IPH to Peers and Sector
Metrics to compare | IPH | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipIPHPeersSector | |
|---|---|---|---|---|
P/E Ratio | −3.8x | −3.0x | −0.7x | |
PEG Ratio | 0.13 | 0.08 | 0.00 | |
Price/Book | 33.8x | 1.4x | 2.6x | |
Price / LTM Sales | 13.8x | 10.5x | 3.4x | |
Upside (Analyst Target) | 222.8% | 139.2% | 37.6% | |
Fair Value Upside | Unlock | 6.1% | 5.3% | Unlock |
Analyst Ratings
2 Buy
1 Hold
0 Sell
Ratings:
3 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 4.8433
(+163.51% Upside)
Earnings
Latest Release
Sep 17, 2025
EPS / Forecast
-0.25 / --
Revenue / Forecast
4.88M / 10.30M
People Also Watch
FAQ
What Stock Exchange Does Innate Pharma Trade On?
Innate Pharma is listed and trades on the Paris Stock Exchange stock exchange.
What Is the Stock Symbol for Innate Pharma?
The stock symbol for Innate Pharma is "IPH."
What Is the Innate Pharma Market Cap?
As of today, Innate Pharma market cap is 170.22M.
What Is Innate Pharma's Earnings Per Share (TTM)?
The Innate Pharma EPS (TTM) is -0.55.
When Is the Next Innate Pharma Earnings Date?
Innate Pharma will release its next earnings report on 12 Nov 2025.
From a Technical Analysis Perspective, Is IPH a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Buy.
How Many Times Has Innate Pharma Stock Split?
Innate Pharma has split 0 times.
How Many Employees Does Innate Pharma Have?
Innate Pharma has 174 employees.
What is the current trading status of Innate Pharma (IPH)?
As of 17 Oct 2025, Innate Pharma (IPH) is trading at a price of 1.8380, with a previous close of 1.95. The stock has fluctuated within a day range of 1.8280 to 1.9420, while its 52-week range spans from 1.3300 to 2.5000.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.